Shire Receives EMA Approval of Lexington Factory

On February 22nd, MBBP client Shire announced that the European Medicines Agency (EMA) has approved the production of its VPRIV enzyme replacement therapies to be made at Shire's new factory in Lexington, MA. With the additional capacity of a second EMA approved facility, Shire will have the ability to significantly increase the global supply of VPRIV while also …

Continue reading Shire Receives EMA Approval of Lexington Factory

FDA Approves Shire’s New Gaucher Drug

MBBP client Shire Human Genetic Therapies, a global specialty biopharmaceutical company, announced last week that the U.S. Food and Drug Administration has approved their new drug VPRIV. VPRIV is a human cell line derived enzyme replacement therapy (ERT) meant to help treat Type 1 Gaucher disease. Shire’s drug has been prescribed to patients before its approval on an …

Continue reading FDA Approves Shire’s New Gaucher Drug